BioMS Medical Corp.

BioMS Medical Corp.

November 08, 2007 08:00 ET

BioMS Medical Corp.-Webcast Alert: Biotech/Pharma/Healthcare On-line Forum

EDMONTON, ALBERTA--(Marketwire - Nov. 8, 2007) - BioMS Medical Corp. (TSX:MS) announces the following Webcast:

What: Biotech/Pharma/Healthcare On-line Forum

When: November 13, 2007 @ 10:30 AM Eastern


How: Live over the Internet - Simply log on to the web at the address

If you are unable to participate during the live webcast, the call will be available for replay at or

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of multiple sclerosis (MS). BioMS Medical has obtained an exclusive worldwide license to a proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The technology, MBP8298, is a synthetic myelin basic protein peptide comprised of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment. MBP8298 is currently being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. MBP8298 is also being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01.

Contact Information